Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
'Pharma bro' Shkreli says he will not testify in securities fraud trial
Source: Reuters
#BUSINESS NEWS
JULY 24, 2017 / 6:10 PM / 14 HOURS AGO
'Pharma bro' Shkreli says he will not testify in securities fraud trial
Brendan Pierson
(Reuters) - Martin Shkreli, the pharmaceutical entrepreneur vilified as the "pharma bro" for raising the price of a life-saving drug by 5,000 percent, said on Monday in federal court that he would not testify in his securities fraud trial.
Shkreli's statement to U.S. District Judge Kiyo Matsumoto came after jurors had been dismissed for the day in the middle of testimony from U.S. prosecutors' last witness in the case, a Federal Bureau of Investigation agent who investigated Shkreli.
Prosecutors could rest their case as early as Tuesday, and closing arguments could come by the end of the week. Jurors heard opening arguments on June 28.
Shkreli, 34, outraged patients and U.S. lawmakers by raising the price of the anti-infection drug Daraprim to $750 a pill, from $13.50, in 2015, when he was chief executive of Turing Pharmaceuticals.
-snip-
JULY 24, 2017 / 6:10 PM / 14 HOURS AGO
'Pharma bro' Shkreli says he will not testify in securities fraud trial
Brendan Pierson
(Reuters) - Martin Shkreli, the pharmaceutical entrepreneur vilified as the "pharma bro" for raising the price of a life-saving drug by 5,000 percent, said on Monday in federal court that he would not testify in his securities fraud trial.
Shkreli's statement to U.S. District Judge Kiyo Matsumoto came after jurors had been dismissed for the day in the middle of testimony from U.S. prosecutors' last witness in the case, a Federal Bureau of Investigation agent who investigated Shkreli.
Prosecutors could rest their case as early as Tuesday, and closing arguments could come by the end of the week. Jurors heard opening arguments on June 28.
Shkreli, 34, outraged patients and U.S. lawmakers by raising the price of the anti-infection drug Daraprim to $750 a pill, from $13.50, in 2015, when he was chief executive of Turing Pharmaceuticals.
-snip-
Read more: http://www.reuters.com/article/us-usa-crime-shkreli-idUSKBN1A92OJ
